Bio-Rad Laboratories Statistics
Total Valuation
BIO has a market cap or net worth of $7.64 billion. The enterprise value is $7.39 billion.
| Market Cap | 7.64B |
| Enterprise Value | 7.39B |
Important Dates
The next estimated earnings date is Thursday, August 1, 2024, after market close.
| Earnings Date | Aug 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BIO has 28.55 million shares outstanding. The number of shares has decreased by -4.07% in one year.
| Shares Outstanding | 28.55M |
| Shares Change (YoY) | -4.07% |
| Shares Change (QoQ) | -0.88% |
| Owned by Insiders (%) | 15.20% |
| Owned by Institutions (%) | 79.83% |
| Float | 19.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 25.12 |
| PS Ratio | 2.93 |
| Forward PS | 2.81 |
| PB Ratio | 0.84 |
| P/FCF Ratio | 41.12 |
| PEG Ratio | 1.19 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 39.77 |
Financial Position
The company has a current ratio of 6.57, with a Debt / Equity ratio of 0.15.
| Current Ratio | 6.57 |
| Quick Ratio | 4.50 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | 7.54 |
| Interest Coverage | -7.99 |
Financial Efficiency
Return on equity (ROE) is -3.70%.
| Return on Equity (ROE) | -3.70% |
| Return on Assets (ROA) | -2.60% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $324,438 |
| Profits Per Employee | -$40,146 |
| Employee Count | 8,030 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 1.58 |
Taxes
| Income Tax | -121.49M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.14% in the last 52 weeks. The beta is 0.95, so BIO's price volatility has been similar to the market average.
| Beta (5Y) | 0.95 |
| 52-Week Price Change | -29.14% |
| 50-Day Moving Average | 283.16 |
| 200-Day Moving Average | 313.05 |
| Relative Strength Index (RSI) | 35.77 |
| Average Volume (20 Days) | 318,661 |
Short Selling Information
The latest short interest is 867,524, so 3.04% of the outstanding shares have been sold short.
| Short Interest | 867,524 |
| Short Previous Month | 653,407 |
| Short % of Shares Out | 3.04% |
| Short % of Float | 4.34% |
| Short Ratio (days to cover) | 4.07 |
Income Statement
In the last 12 months, BIO had revenue of $2.61 billion and -$322.37 million in losses. Loss per share was -$10.69.
| Revenue | 2.61B |
| Gross Profit | 1.39B |
| Operating Income | 320.59M |
| Pretax Income | -443.86M |
| Net Income | -322.37M |
| EBITDA | -394.48M |
| EBIT | -394.48M |
| Loss Per Share | -$10.69 |
Balance Sheet
The company has $1.65 billion in cash and $1.40 billion in debt, giving a net cash position of $251.51 million or $8.81 per share.
| Cash & Cash Equivalents | 1.65B |
| Total Debt | 1.40B |
| Net Cash | 251.51M |
| Net Cash Per Share | $8.81 |
| Equity (Book Value) | 9.05B |
| Book Value Per Share | 317.07 |
| Working Capital | 2.59B |
Cash Flow
In the last 12 months, operating cash flow was $346.62 million and capital expenditures -$160.89 million, giving a free cash flow of $185.72 million.
| Operating Cash Flow | 346.62M |
| Capital Expenditures | -160.89M |
| Free Cash Flow | 185.72M |
| FCF Per Share | $6.51 |
Margins
Gross margin is 53.37%, with operating and profit margins of 12.31% and -12.37%.
| Gross Margin | 53.37% |
| Operating Margin | 12.31% |
| Pretax Margin | -17.04% |
| Profit Margin | -12.37% |
| EBITDA Margin | -15.14% |
| EBIT Margin | -15.14% |
| FCF Margin | 7.13% |
Dividends & Yields
BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.07% |
| Shareholder Yield | 4.07% |
| Earnings Yield | -4.22% |
| FCF Yield | 2.43% |
Analyst Forecast
The average price target for BIO is $410.00, which is 53.24% higher than the current price. The consensus rating is "Buy".
| Price Target | $410.00 |
| Price Target Difference | 53.24% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 3.35% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on March 8, 2002. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 8, 2002 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
BIO has an Altman Z-Score of 2.71 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.71 |
| Piotroski F-Score | 4 |